Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC

作者：Hexiao Tang, Yuquan Bai, Gaofeng Pan, Xianguo Wang, Yanhong Wei, Zetian Yang, Jinping Zhao · 发表于：Autoimmunity · 年份：2018 · DOI：10.1080/08916934.2018.1550079 · 被引用次数：20 · 研究领域：Cancer, Hypoxia, and Metabolism、Growth Hormone and Insulin-like Growth Factors、Cytokine Signaling Pathways and Interactions

The signaling pathways of interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) play an important role in the progression of lung cancer, and this study aimed to explore whether they can synergistically promote the progression of non-small cell lung cancer (NSCLC). We found that IL-6, glycoprotein 130 (GP130), IGF-1 and IGF-1R were highly expressed in NSCLC (p = .000), and there was the correlation between GP130, IGF-1, and IGF-1R (p < .01). The overall survival of patients with the co-expression of GP130 and IGF-1R was significantly shorter (p = .0360). Co-stimulation of IL-6 and IGF-1 resulted in significantly enhanced in cell proliferation, (p < .05), invasion (p < .05), cycle (p < .05), apoptosis (p < .05), and the expression of signal molecules (GP130, IGF-1R, p-AKT, and p-ERK1/2) (all p < .05) in NSCLC cells. This experiment revealed that IL-6 and IGF-1 can synergistically promote the progression of NSCLC. The high expression of GP130 and IGF-1R is an independent risk factor for poor prognosis patients, and it is helpful to find a more accurate target for targeted therapy in NSCLC.